These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 22241465

  • 1. The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.
    Sheehan NL, van Heeswijk RP, Foster BC, Akhtar H, Singhal N, Seguin I, DelBalso L, Bourbeau M, Chauhan BM, Boulassel MR, Burger DM, Lalonde RG, Cameron DW.
    Molecules; 2012 Jan 12; 17(1):688-702. PubMed ID: 22241465
    [Abstract] [Full Text] [Related]

  • 2. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH.
    Antivir Ther; 2004 Feb 12; 9(1):77-84. PubMed ID: 15040539
    [Abstract] [Full Text] [Related]

  • 3. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
    Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM, COPHAR2- ANRS Study Group.
    Br J Clin Pharmacol; 2008 Apr 12; 65(4):548-57. PubMed ID: 17922881
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
    Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathôt RA, Huitema AD, Beijnen JH.
    Pediatr Infect Dis J; 2006 Jun 12; 25(6):538-43. PubMed ID: 16732153
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
    Panhard X, Goujard C, Legrand M, Taburet AM, Diquet B, Mentré F, COPHAR 1-ANRS study group.
    Br J Clin Pharmacol; 2005 Oct 12; 60(4):390-403. PubMed ID: 16187971
    [Abstract] [Full Text] [Related]

  • 6. Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
    Bergshoeff AS, Wolfs TF, Geelen SP, Burger DM.
    Ann Pharmacother; 2003 Apr 12; 37(4):521-5. PubMed ID: 12659608
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.
    Read JS, Best BM, Stek AM, Hu C, Capparelli EV, Holland DT, Burchett SK, Smith ME, Sheeran EC, Shearer WT, Febo I, Mirochnick M.
    HIV Med; 2008 Nov 12; 9(10):875-82. PubMed ID: 18795962
    [Abstract] [Full Text] [Related]

  • 8. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.
    van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW.
    Clin Pharmacol Ther; 2004 Dec 12; 76(6):588-97. PubMed ID: 15592330
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
    Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, Jacqz-Aigrain E, Paediatric European Network for Treatment of AIDS Executive Committee.
    Pediatr Infect Dis J; 2003 Jan 12; 22(1):48-55. PubMed ID: 12544409
    [Abstract] [Full Text] [Related]

  • 10. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
    Regazzi M, Maserati R, Villani P, Cusato M, Zucchi P, Briganti E, Roda R, Sacchelli L, Gatti F, Delle Foglie P, Nardini G, Fabris P, Mori F, Castelli P, Testa L.
    Antimicrob Agents Chemother; 2005 Feb 12; 49(2):643-9. PubMed ID: 15673746
    [Abstract] [Full Text] [Related]

  • 11. Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.
    Damle BD, Uderman H, Biswas P, Crownover P, Lin C, Glue P.
    Br J Clin Pharmacol; 2009 Nov 12; 68(5):682-9. PubMed ID: 19916992
    [Abstract] [Full Text] [Related]

  • 12. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
    Fang AF, Damle BD, LaBadie RR, Crownover PH, Hewlett D, Glue PW.
    Pharmacotherapy; 2008 Jan 12; 28(1):42-50. PubMed ID: 18154473
    [Abstract] [Full Text] [Related]

  • 13. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
    Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM, COPHAR1-ANRS 102 Study Group.
    Clin Pharmacokinet; 2005 Jan 12; 44(12):1267-78. PubMed ID: 16372824
    [Abstract] [Full Text] [Related]

  • 14. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
    Kruse G, Esser S, Stocker H, Breske A, Koerber A, Kopperman M, Wiehler H, Ross B, Möcklinghoff C, Hill A, Becker M, Kurowski M.
    Antivir Ther; 2005 Jan 12; 10(2):349-55. PubMed ID: 15865230
    [Abstract] [Full Text] [Related]

  • 15. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
    Khaliq Y, Gallicano K, Seguin I, Fyke K, Carignan G, Bulman D, Badley A, Cameron DW.
    Br J Clin Pharmacol; 2000 Aug 12; 50(2):108-15. PubMed ID: 10930962
    [Abstract] [Full Text] [Related]

  • 16. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
    Payen S, Faye A, Compagnucci A, Giaquinto C, Gibbs D, Gomeni R, Bressolle F, Jacqz-Aigrain E.
    Antimicrob Agents Chemother; 2005 Feb 12; 49(2):525-35. PubMed ID: 15673728
    [Abstract] [Full Text] [Related]

  • 17. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
    Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S.
    Antimicrob Agents Chemother; 2006 Jun 12; 50(6):2079-86. PubMed ID: 16723569
    [Abstract] [Full Text] [Related]

  • 18. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
    Stocker H, Herzmann C, Breske A, Kruse G, Berger M, Schulbin H, Hill A, Steinmüller J, Becker M, Arastéh K, Kurowski M.
    J Antimicrob Chemother; 2007 Mar 12; 59(3):560-4. PubMed ID: 17255144
    [Abstract] [Full Text] [Related]

  • 19. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA, Weiner MH, Burman WJ, Vernon AA, Zhao ZA, Khan AE, Jones BE, Sandman L, Engle M, Silva-Trigo C, Hsyu PH, Becker MI, Peloquin CA, Tuberculosis Trials Consortium.
    Pharmacotherapy; 2007 Jun 12; 27(6):793-800. PubMed ID: 17542762
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
    Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, Watts DH, Huang S, Hughes MD, Kaiser K, Purdue L, Asfaw Y, Keller M, Smith E, PACTG 353 Team.
    HIV Clin Trials; 2008 Jun 12; 9(2):115-25. PubMed ID: 18474496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.